L&G Pharma Breakthrough UCITS ETF (ETR:ETLI)

Germany flag Germany · Delayed Price · Currency is EUR
9.15
+0.09 (1.00%)
Jul 2, 2025, 5:36 PM CET
0.04%
Assets 21.43M
Expense Ratio 0.49%
PE Ratio n/a
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Frequency n/a
Payout Ratio n/a
1-Year Return -0.58%
Volume 1,846
Open 9.09
Previous Close 9.06
Day's Range 9.09 - 9.18
52-Week Low 8.14
52-Week High 10.66
Beta 0.41
Holdings 40
Inception Date Jan 18, 2018

About ETLI

The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.

Category Sector Equity Biotechnology
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ETLI

Performance

ETLI had a total return of -0.58% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.29%.

Top 10 Holdings

33.42% of assets
Name Symbol Weight
InnoCare Pharma Limited 9969 3.79%
Pharming Group N.V. PHARM 3.71%
Alnylam Pharmaceuticals, Inc. ALNY 3.70%
BioCryst Pharmaceuticals, Inc. BCRX 3.41%
Ionis Pharmaceuticals, Inc. IONS 3.30%
Kyowa Kirin Co., Ltd. 4151 3.14%
Zevra Therapeutics, Inc. ZVRA 3.12%
Xeris Biopharma Holdings, Inc. XERS 3.11%
Chugai Pharmaceutical Co., Ltd. 4519 3.09%
Royalty Pharma plc RPRX 3.05%
View More Holdings